148 completed, 48 recruiting, 35 unknown, 34 terminated. 90 Phase 2, 79 Not applicable, 48 Phase 1, 43 Phase 3, 7 Phase 4.
Follow Scleroderma, Diffuse: new trials by email Literature Review of Scleroderma, Diffuse trials Research Report on Scleroderma, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy C-CAR168 - Systemic Sclerosis (SSc), Systemic Sclerosis | Phase 1 | Not yet recruiting | AbelZeta Inc. | 12 | 2027-03-01 | 2026-10-13 |
| A Clinical Study on Systemic Sclerosis and the Validation of French-language Questionnaires Assessing Disability, Quality of Life, and Disease Status. Questionnaires - Scleroderma | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 200 | 2026-11-01 | 2026-10-22 | |
| A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases BMS-986553 - Systemic Lupus Erythematosus, Sjögren's Disease | Phase 1 | Not yet recruiting | Bristol-Myers Squibb | 60 | 2026-10-30 | 2026-10-14 |
| Home-based Exercise for Improving Health-related Quality of Life in Systemic Sclerosis Home-based exercise programme, Usual Care - Systemic Sclerosis (SSc) | Not applicable | Not yet recruiting | University of Aarhus | 270 | 2026-10-15 | 2026-09-25 |
| TL1A Inhibition in Systemic Sclerosis-Related Skin Fibrosis and Immunological Alterations: A Proof-of-Concept In Vitro Study (FIBROSTOP) TL1A stimulation and inhibition (in vitro) - Systemic Sclerosis (SSc), Diffuse Cutaneous Systemic Sclerosis | Not yet recruiting | Fondazione Policlinico Universitario Campus Bio-Medico | 20 | 2026-09-01 | 2026-06-11 | |
| Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases Allogeneic CD19/BCMA-targeted CAR-γδT cell injection, Cyclophosphamide, Fludarabine - Refractory/Relapsed Systemic Lupus Erythematosus, Refractory / Relapsed / Progressive Systemic Sclerosis | Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 9 | 2026-07-01 | 2026-06-09 |
| US Zamto-cel Autoimmune Diseases zamtocabtagene autoleucel, Cyclophosphamide, Fludarabine - Lupus Nephritis, Systemic Lupus Erythematosus | Phase 1 | Recruiting | Miltenyi Biomedicine GmbH | 48 | 2026-07-01 | 2026-06-11 |
| Personalized Online Occupational Therapy Intervention for Adults With Scleroderma Personalized Online Occupational Therapy Intervention, Usual Care - Scleroderma, Scleroderma (Limited and Diffuse) | Not applicable | Completed | Universidad de Zaragoza | 24 | 2026-05-16 | 2026-10-14 |
| The Effect of Progressive Muscle Relaxation Exercises on Fatigue, Dyspnea, and Respiratory Function in Patients With Systemic Sclerosis Progressive Muscle Relaxation Exercise - Systemic Sclerosis (SSc) | Not applicable | Recruiting | University of Gaziantep | 50 | 2026-04-25 | 2026-10-08 |
| EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc) MTX-474, Placebo - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Recruiting | Mediar Therapeutics | 85 | 2026-04-16 | 2026-10-05 |
| Controlling Hyperactive Immunity With Long-lived Lymphocytes QEL-005 - Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA) | Phase 1 / Phase 2 | Recruiting | Quell Therapeutics Limited | 16 | 2026-04-10 | 2026-10-19 |
| Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases EVM18001 Injection - System Lupus Erythematosus(SLE), Scleroderma | Not applicable | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 12 | 2026-03-12 | 2026-03-13 |
| YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Diffuse Systemic Sclerosis | Phase 1 | Not yet recruiting | Children's Hospital of Fudan University | 12 | 2026-03-01 | 2026-02-27 |
| A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases XmAb657 - Healthy, Idiopathic Inflammatory Myopathies | Phase 1 | Recruiting | Xencor, Inc. | 60 | 2026-02-24 | 2026-08-03 |
| A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis Nemolizumab, Placebo - Systemic Sclerosis | Phase 2 | Recruiting | Galderma R&D | 162 | 2026-02-20 | 2026-03-31 |
| Transcriptomic Study of Cutaneous Fibroblasts in Scleroderma Skin samples, Analysis of fibroblasts - Scleroderma | Recruiting | Centre Hospitalier Universitaire Dijon | 60 | 2026-01-26 | 2026-01-29 | |
| Evaluating Tools to Communicate Scleroderma Research Results to Patients - Trial #1 Plain-language summary, Dissemination Tool (Infographic) - Scleroderma, Systemic Sclerosis | Not applicable | Completed | Lady Davis Institute | 511 | 2025-12-05 | 2026-09-10 |
| Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With Scleroderma Cognitive Exercise Therapy Approach, Control group - Scleroderma, Scleroderma, Localized | Not applicable | Recruiting | Hacettepe University | 48 | 2025-12-04 | 2025-12-18 |
| A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease ALLO-329, Cyclophosphamide, Fludarabine - Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy | Phase 1 | Recruiting | Allogene Therapeutics | 66 | 2025-11-13 | 2026-09-10 |
| Diffuse Cutaneous Scleroderma (DSSc) SFDI Study Spatial-frequency domain imaging (SFDI) - Systemic Scleroderma, Diffuse Cutaneous Scleroderma | Not applicable | Recruiting | Boston University | 65 | 2025-11-06 | 2026-07-23 |
Showing 20 of 308. Sign in to see all of them.
Scleroderma, Systemic (149) · Lung Diseases, Interstitial (27) · Autoimmune Diseases (26) · Lupus Erythematosus, Systemic (26) · Arthritis, Rheumatoid (24) · Raynaud Disease (22) · Myositis (20) · Sjogren's Syndrome (20) · Dermatomyositis (14) · Connective Tissue Diseases (13) · Hypertension, Pulmonary (12) · Scleroderma, Localized (11) · digital ulcers (11) · Skin Diseases (9)
Skin and Connective Tissue Diseases (308) · Skin Diseases (299) · Connective Tissue Diseases (295) · Scleroderma, Systemic (159) · Cardiovascular Diseases (56) · Immune System Diseases (53) · Vascular Diseases (53) · Pathological Conditions, Signs and Symptoms (51) · Respiratory Tract Diseases (50) · Musculoskeletal Diseases (48) · Lung Diseases (47) · Pathologic Processes (39) · Nervous System Diseases (37) · Joint Diseases (34) · Skin Diseases, Vascular (33)
Cyclophosphamide (16) · Mycophenolic Acid (9) · fludarabine (9) · Rituximab (7) · Blood Specimen Collection (6) · Bosentan (6) · Nitroglycerin (5) · Immunoglobulins, Intravenous (4) · Tadalafil (4) · Botulinum Toxins, Type A (3) · Brentuximab Vedotin (3) · Imatinib Mesylate (3) · Methotrexate (3) · Sildenafil Citrate (3) · Surveys and Questionnaires (3)
University of Michigan (15) · Johns Hopkins University (9) · Lady Davis Institute (9) · Assistance Publique - Hôpitaux de Paris (7) · Istanbul University (6) · Assiut University (5) · Bristol-Myers Squibb (5) · Duke University (5) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (5) · MediQuest Therapeutics (5) · University Hospital, Strasbourg, France (5) · Actelion (4) · Boston University (4) · Federal University of São Paulo (4) · Hacettepe University (4)
United States (151) · France (40) · Canada (34) · United Kingdom (31) · Turkey (Türkiye) (26) · Spain (25) · Italy (23) · Germany (21) · Poland (19) · Australia (16) · Brazil (13) · China (13) · Netherlands (12) · Argentina (11) · Mexico (11)
Robert Lafyatis, MD (4) · James Seibold, MD (3) · Luc Mouthon, MD, PhD (3) · Brett D Thombs, PhD (2) · Brett Thombs, PhD (2) · Dana DiRenzo, MD (2) · David Launay, MD,PhD (2) · Dinesh Khanna, MD (2) · Dinesh Khanna, MD, MS (2) · George Georges (2) · Houman Hemmati, MD (2)
PMID 41217519, PMID 29381834, PMID 33481429, PMID 33765691, PMID 37929840, PMID 11934971, PMID 12355489, PMID 15692967, PMID 16738459, PMID 16790698, PMID 16840399, PMID 17469162, PMID 17485423, PMID 17717203, PMID 17901414, PMID 17974598, PMID 18512816, PMID 18641099, PMID 19207142, PMID 19776222, PMID 19892673, PMID 19950289, PMID 20392703, PMID 20506355, PMID 20576211, PMID 20740615, PMID 20805294, PMID 20837499, PMID 21312348, PMID 21951278, PMID 22470237, PMID 23039171, PMID 23402088, PMID 23494072, PMID 23554239, PMID 23597147, PMID 24054756, PMID 24067785, PMID 24092682, PMID 24459219, PMID 24559157, PMID 24812476, PMID 24850877, PMID 25274889, PMID 25452309, PMID 25826322, PMID 25995322, PMID 26071192, PMID 26098215, PMID 27077744
2023 (8), 2025 (2), 1UM1AI110557 (1), 2015 (1), 2018 (1), 2019 (1), K23AR002187 (1), N01AR002251 (1), R01AI041721 (1), R01AR047219 (1), R01AR085317 (1), R01HL089758 (1), R01HL089901 (1), R01HL114910 (1), R21AR065089 (1)